News & Updates
Showing Neurology articles
Showing
Show Multimedia Only

Donanemab puts brakes on Alzheimer’s disease progression
26 Jul 2023
In the treatment of individuals with early symptomatic Alzheimer's disease and amyloid and tau pathology, the immunoglobulin G1 monoclonal antibody donanemab helps slow clinical progression, according to the results of the phase III TRAILBLAZER-ALZ 2 study.
26 Jul 2023







